Method of evaluating drug efficacy and toxicity

• US 7,049,103 B2
• Filed: 10/09/2002
• Issued: 05/23/2006
• Est. Priority Date: 10/10/2001
• Status: Expired due to Fees

• Current Assignee: Tosoh Corporation
• Original Assignee: Tosoh Corporation
• Inventors: Yasukawa, Kiyoshi, Tsuchiya, Shigeo, Ishiguro, Takahiko
• Primary Examiner(s): Horlick, Kenneth R.
• Assistant Examiner(s): WILDER, CYNTHIA B
• Application Number:
  US10/266,605
• Publication Number:
  US 20030108930A1
• Time in Patent Office: 1,322 Days
• Field of Search: 436/6, 435/91.1, 435/91.2, 536/23.1, 536/24.33, 536/24.32, 536/25.32
• US Class Current: 435/91.2
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/5014 for testing toxicity

Abstract

A method of assaying the efficacy and/or toxicity of a test substance by expression of a specific gene in a cell or a microorganism, which comprises treating the cell or the microorganism with the test substance, a step of amplifying an RNA having a sequence homologous or complementary to a specific sequence in a target RNA obtained as the result of transcription of the specific gene, and a step of determining whether the target RNA is transcribed through the expression of the specific gene by detecting the RNA amplified in the previous amplification step.

Claims

1. A method of assaying the efficacy andlor toxicity of a test substance by expression of a specific gene in a cell or a microorganism, which comprises:

(a) treating the cell or the microorganism with the test substance,

(b) extracting nucleic acids from the cell or the microorganism to provide a reaction solution,

(c) amplifying, from said reaction solution containing nucleic acids, a target RNA having a sequence homologous or complementary to a specific sequence in a target mRNA in the reaction solution which is obtained by said extracting by a method comprising,

synthesizing a cDNA of the target RNA with an RNA-dependent DNA polymerase,

degrading the RNA strand in the resulting RNA•

DNA hydrid with ribonuclease H to leave a single-stranded DNA,

forming a double-stranded DNA having a promoter sequence which can be transcribed into an RNA comprising the specific base sequence or a sequence complementary to the specific base sequence by using the single-stranded DNA as a template for a DNA-dependent DNA polymerase,

transcribing the double-stranded DNA into an RNA transcript,

synthesizing a cDNA from the RNA transcript as a template by catalysis of an RNA-dependent DNA polymerase, and

amplifying the target RNA with a first oligonucleotide and a second oligonucleotide consisting of at least 10 consecutive bases in the cDNA,

(d) determining whether the target mRNA is transcribed through the expression of the specific gene by detecting the RNA amplified by said amplifying, and

(e) assessing the efficacy and/or toxicity of said test substance by expression of the specific gene compared to expression of said the specific gene when in the absence of said test substance,

wherein (c) and (d) are performed simultaneously.

2. The method according to claim 1, wherein said detecting comprises

adding to the reaction solution an oligonucleotide probe labeled with a fluorescent intercalative dye which hybridizes to the amplified RNA and

measuring the change in the fluorescence of the reaction solution.

3. The method according to claim 1, wherein either said first oligonucleotide or said second oligonucleotide has a promoter sequence for an RNA polymerase at the 5′

end.

4. The method according to claim 1, wherein expression of the specific gene encodes an acute phase response protein expressed in inflamed hepatic cells.

5. The method according to claim 1, wherein expression of the specific gene encodes a stress protein expressed in differentiating vascular smooth muscle cells.

6. The method according to claim 1, wherein said amplifying is performed isothermally.